Cardinal Health Receives Patent For Mammalian Cell Genetic Engineering Technology

SOMERSET, N.J.--(BUSINESS WIRE)--April 4, 2005--Cardinal Health, the leading provider of products and services supporting the health care industry, today announced it has been granted its first patent for an innovative technology that will help in the mass production of biopharmaceuticals. The company received U.S. Patent No. 6,852,510, entitled "Host Cells Containing Multiple Integrating Vectors", for its gene product expression technology platform. The technology, which Cardinal Health makes available to its customers for the development of their proprietary biomolecules, is marketed under the trademark "GPExTM".